Patricia Inacio, PhD, science writer —

A new review article entitled “Why industry propaganda and political interference cannot disguise the inevitable role played by human exposure to aluminum in neurodegenerative diseases, including Alzheimer’s disease,” published in Frontiers in Neurology, argues the role of aluminum in the development of Alzheimer’s disease. The study author,…

Avanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer’s disease (AD). The data is set to be presented at the American Neurological Association’s (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated…

The 2014 Nobel prize in physiology or medicine was recently awarded to three scientists for their discovery of brains’ cells that report animals’ position in space, which therefore is being referred to as the brain’s “internal GPS.” The prize is divided between John O’Keefe, PhD, director of the Sainsbury…

According to researchers, moody, jealous women in mid-life may in fact face a higher risk of developing Alzheimer’s late in life. A new study entitled “Midlife personality and risk of Alzheimer disease and distress” published in the journal Neurology suggests that an increased risk to…

A new study entitled “Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo” published in September issue of Stem Cell Research & Therapy suggests Curcuma long active element Aromatic turmerone induces neural stem cells’ (NSCs) proliferation and differentiation in vivo, a key event for overcoming…

A new study entitled “Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease,” published in the online issue of Neuron, reports the discovery of a key pathway to the progression of Alzheimer’s Disease. Alzheimer’s disease is characterized by synaptic…

Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer’s disease patients. The results will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir,…

The identification of a genetic variant may lead to improved diagnostics for predicting the onset of Alzheimer’s disease. Amyloid-beta (Aβ) is the main component of amyloid plaques, i.e., extracellular deposits in the brains of patients with Alzheimer’s disease. Now, a new study entitled “Apolipoprotein E Genotype and…